FTXH News and Press, First Trust Nasdaq Pharmaceuticals ETF From 10/04/22

Summary We expect macro headwinds will continue to pressure U.S. corporate earnings in the coming months. We expect earnings expectations to decline as multinational firms realize foreign exchange headwinds that accelerated over the past year. Investors can avoid undue interna...

Summary With inflation at the highest level in decades and volatility continuing to surge, equity investors are questioning their next moves. At the beginning of the year, financial conditions were very loose by any means historically, and we've very rapidly moved from loose finan...

Summary Jackson Hole reset expectations to focus more on inflation. The U.S. dollar should stabilize over the medium-term amid hawkishness from other central banks and slowing economic data. At stake is Europe’s ability to refill their storage tanks ahead of winter. ...

Summary We believe that cash flow and debt sustainability are likely to become increasingly important as real economic growth slows and credit access tightens. Cash flow provides a link between a company’s income statement and their balance sheet. Focusing on the Russel...

Summary Today's market X-ray shows the returns for each index, asset class, sector, and so on, since the recent low point on June 16th. Of the global indices, US small caps are in the lead, followed by the NASDAQ. High beta stocks are the most preferred factors since June 16. ...

Summary The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry’s long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025. ...

Today, we circle back on Precigen, a biotech firm that was once part of Intrexon. Precigen is advancing several drug candidates in its pipeline and recently agreed to a divesture than significantly bolstered its financial situation. An investment analysis of Precigen follows in th...

Both the FY 2022 top line and bottom line for CSL didn't meet the market's expectations, with the weakness associated with the core Behring business segment being a key factor. The FY 2023 outlook for CSL is better than management guidance suggested, taking into account one-off items....

Why health care stocks may outperform the broader market in the long run. Is now the time to consider health care stocks? Why health care is still a good way for investors to play defense. Greg Bonnell: Many health care stocks are down from the highs put in e...

Catalent has built up a solid track record of value creation over the past nearly decade long period. The company has seen excellent operating momentum, despite the pandemic being on its retreat. With shares lagging, valuations have become a lot more compelling, not to be confused...